Kindbody Acquires Phosphorus Labs
June 7, 2022
Kindbody has acquired Phosphorus Labs, a preventative genomics and clinical genetic-testing company, including Phosphorus’s 8,000 sq. ft. reference laboratory in Secaucus, New Jersey. The acquisition brings genetic testing and carrier screening capabilities in-house as Kindbody creates its KindLabs division to integrate diagnostics into its end-to-end fertility and family-building care.
- Buyers
- Kindbody
- Targets
- Phosphorus Labs
- Industry
- Biotechnology
- Location
- New York, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Labcorp Acquires Personal Genome Diagnostics (PGDx)
February 21, 2022
Healthcare Services
Labcorp completed its acquisition of Personal Genome Diagnostics (PGDx), a cancer genomics company that develops liquid biopsy and tissue-based NGS products. Labcorp paid $450 million in cash at closing plus up to $125 million in performance-based milestones to expand its oncology genomics and liquid biopsy capabilities and accelerate access to precision diagnostics for clinical care and trials.
-
healthŌme Acquires Kailos Genetics
May 31, 2023
Biotechnology
healthŌme Inc. has acquired Kailos Genetics, a CLIA-certified and CAP-accredited genetic testing laboratory, making Kailos a wholly-owned subsidiary to expand healthŌme's genomics testing capabilities. The deal integrates Kailos' laboratory facilities, proprietary sequencing workflow and reagent supply capabilities into healthŌme's precision health management platform, expanding distribution into life and critical illness insurance channels and broader healthcare and life-science markets.
-
ProPhase Labs Acquires Nebula Genomics
August 11, 2021
Biotechnology
ProPhase Labs, through its newly formed subsidiary ProPhase Precision Medicine, completed the acquisition of Nebula Genomics, a privately owned whole‑genome sequencing and personal genomics company. The deal (approximately $14.6 million in a mix of cash and ProPhase common stock) will integrate Nebula’s whole genome sequencing capabilities and DTC platform into ProPhase’s CLIA-certified molecular testing laboratories to expand diagnostic and consumer genomics offerings.
-
Praesidian Capital Acquires Undisclosed Genetics Business
September 18, 2019
Healthcare Services
Praesidian Capital announced the acquisition of an integrated clinical and laboratory services company operating in genetic medicine, focused on prenatal and preconception testing and hereditary cancer risk assessments. The deal is Praesidian’s first as an independent sponsor and will serve as a platform for national expansion and future add-on acquisitions.
-
LabCorp Acquires MNG Laboratories from HealthEdge
March 4, 2019
Healthcare Services
LabCorp has acquired MNG Laboratories, an Atlanta-based clinical diagnostic provider specializing in neurogenetics and next-generation sequencing, from HealthEdge Investment Partners' Fund II. The acquisition expands LabCorp’s neurology and neurogenetics testing capabilities and makes MNG’s testing services available through LabCorp’s Covance drug development business.
-
LabGenomics USA LLC Acquires QDx Pathology
September 5, 2023
Healthcare Services
LabGenomics USA LLC, a subsidiary of South Korea–based LabGenomics Co., Ltd., has acquired QDx Pathology, a U.S. clinical and molecular pathology laboratory. The deal, signed in August 2023, is intended to accelerate LabGenomics' entry and expansion into the North American diagnostics market by combining QDx's lab services with LabGenomics' NGS-based molecular diagnostics capabilities.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.